Efatutazone

Drug Profile

Efatutazone

Alternative Names: CS-7017; Inolitazone; RS-5444

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antineoplastics; Thiazolidinediones
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Non-small cell lung cancer; Thyroid cancer

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 31 Jul 2013 Discontinued - Phase-I for Colorectal cancer in Japan (PO)
  • 31 Jul 2013 Discontinued - Phase-I for Non-small cell lung cancer (first-line therapy, metastatic disease, combination therapy) in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top